These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25993548)

  • 1. Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer.
    Thompson ML; Jimenez-Andrade JM; Chartier S; Tsai J; Burton EA; Habets G; Lin PS; West BL; Mantyh PW
    Pain; 2015 Sep; 156(9):1692-1702. PubMed ID: 25993548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone.
    Halvorson KG; Kubota K; Sevcik MA; Lindsay TH; Sotillo JE; Ghilardi JR; Rosol TJ; Boustany L; Shelton DL; Mantyh PW
    Cancer Res; 2005 Oct; 65(20):9426-35. PubMed ID: 16230406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antinociceptive effect of prostatic acid phosphatase in a rat model of cancer-induced bone pain.
    Chen L; Zhu L; Wang K; Wang W; Mei XP; Liu T; Zhang FX; Wang W; Chen T; Li YQ
    Pain Physician; 2013; 16(6):533-46. PubMed ID: 24284839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain.
    Forte BL; Slosky LM; Zhang H; Arnold MR; Staatz WD; Hay M; Largent-Milnes TM; Vanderah TW
    Pain; 2016 Dec; 157(12):2709-2721. PubMed ID: 27541850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain.
    Jimenez-Andrade JM; Bloom AP; Stake JI; Mantyh WG; Taylor RN; Freeman KT; Ghilardi JR; Kuskowski MA; Mantyh PW
    J Neurosci; 2010 Nov; 30(44):14649-56. PubMed ID: 21048122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
    Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
    J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of Spinal Bv8/Prokineticin 2 in a Rat Model of Cancer-Induced Bone Pain.
    Hang LH; Luo H; Li SN; Shu WW; Chen Z; Chen YF; Yuan JF; Shi LL; Shao DH
    Basic Clin Pharmacol Toxicol; 2015 Sep; 117(3):180-5. PubMed ID: 25641661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain.
    Appel CK; Gallego-Pedersen S; Andersen L; Blancheflor Kristensen S; Ding M; Falk S; Sayilekshmy M; Gabel-Jensen C; Heegaard AM
    Sci Rep; 2017 Jul; 7(1):4792. PubMed ID: 28684771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calpain inhibitor reduces cancer-induced bone pain possibly through inhibition of osteoclastogenesis in rat cancer-induced bone pain model.
    Xu JY; Jiang Y; Liu W; Huang YG
    Chin Med J (Engl); 2015 Apr; 128(8):1102-7. PubMed ID: 25881607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone pain.
    Muralidharan A; Wyse BD; Smith MT
    Pain Med; 2014 Jan; 15(1):93-110. PubMed ID: 24433468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of spinal neuroimmune responses by prolonged morphine treatment in a rat model of cancer induced bone pain.
    Cao F; Gao F; Xu AJ; Chen ZJ; Chen SS; Yang H; Yu HH; Mei W; Liu XJ; Xiao XP; Yang SB; Tian XB; Wang XR; Tian YK
    Brain Res; 2010 Apr; 1326():162-73. PubMed ID: 20176002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rat model of bone cancer pain.
    Medhurst SJ; Walker K; Bowes M; Kidd BL; Glatt M; Muller M; Hattenberger M; Vaxelaire J; O'Reilly T; Wotherspoon G; Winter J; Green J; Urban L
    Pain; 2002 Mar; 96(1-2):129-40. PubMed ID: 11932069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain.
    Slosky LM; BassiriRad NM; Symons AM; Thompson M; Doyle T; Forte BL; Staatz WD; Bui L; Neumann WL; Mantyh PW; Salvemini D; Largent-Milnes TM; Vanderah TW
    Pain; 2016 Nov; 157(11):2605-2616. PubMed ID: 27482630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.
    Ao JY; Zhu XD; Chai ZT; Cai H; Zhang YY; Zhang KZ; Kong LQ; Zhang N; Ye BG; Ma DN; Sun HC
    Mol Cancer Ther; 2017 Aug; 16(8):1544-1554. PubMed ID: 28572167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
    Manthey CL; Johnson DL; Illig CR; Tuman RW; Zhou Z; Baker JF; Chaikin MA; Donatelli RR; Franks CF; Zeng L; Crysler C; Chen Y; Yurkow EJ; Boczon L; Meegalla SK; Wilson KJ; Wall MJ; Chen J; Ballentine SK; Ott H; Baumann C; Lawrence D; Tomczuk BE; Molloy CJ
    Mol Cancer Ther; 2009 Nov; 8(11):3151-61. PubMed ID: 19887542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain-derived neurotrophic factor modulates N-methyl-D-aspartate receptor activation in a rat model of cancer-induced bone pain.
    Wang LN; Yang JP; Ji FH; Zhan Y; Jin XH; Xu QN; Wang XY; Zuo JL
    J Neurosci Res; 2012 Jun; 90(6):1249-60. PubMed ID: 22354476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear factor kappa B regulated monocyte chemoattractant protein-1/chemokine CC motif receptor-2 expressing in spinal cord contributes to the maintenance of cancer-induced bone pain in rats.
    Wang Y; Ni H; Li H; Deng H; Xu LS; Xu S; Zhen Y; Shen H; Pan H; Yao M
    Mol Pain; 2018; 14():1744806918788681. PubMed ID: 29956585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel immunocompetent model of metastatic prostate cancer-induced bone pain.
    Liu Z; Murphy SF; Huang J; Zhao L; Hall CC; Schaeffer AJ; Schaeffer EM; Thumbikat P
    Prostate; 2020 Jul; 80(10):782-794. PubMed ID: 32407603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2Y1 purinoceptor inhibition reduces extracellular signal-regulated protein kinase 1/2 phosphorylation in spinal cord and dorsal root ganglia: implications for cancer-induced bone pain.
    Chen J; Wang L; Zhang Y; Yang J
    Acta Biochim Biophys Sin (Shanghai); 2012 Apr; 44(4):367-72. PubMed ID: 22349022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
    Fujita H; Gomori A; Fujioka Y; Kataoka Y; Tanaka K; Hashimoto A; Suzuki T; Ito K; Haruma T; Yamamoto-Yokoi H; Harada N; Sakuragi M; Oda N; Matsuo K; Inada M; Yonekura K
    PLoS One; 2016; 11(10):e0164830. PubMed ID: 27736957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.